Episurf improved Q3 results with higher revenues and lower costs, expanded its US sales force, and raised SEK 90m via a rights issue. Regulatory progress continues, with 510(k) clearance for the big toe implant expected in early 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.